Betty Rachma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Betty Rachma has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Henry Sutanto
Internal Medicine Specialist Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
7 shared publications - Yuliasih Yuliasih
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
2 shared publications Ani Widyastuti
Klinik Media Farma Samarinda
1 shared publication- Arinditia Triasti Putri
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication - Arlinda Silva Prameswari
Departement of Anatomy, Faculty of Medicine, Universitas Muhammadiyah Sidoarjo, Indonesia & Department of Emergency Medicine, Pusura Candi Hospital, Sidoarjo
1 shared publication Awalia Awalia
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in npj Biological Physics and Mechanics
- Vol. 3 (1) , 21
Extracellular matrix regulation of YAP and TAZ signaling mechanobiology and therapeutic opportunities
- 1 October 2026
- Published by Springer Nature in npj Biological Physics and Mechanics
- Vol. 3 (1) , 21
Open AccessExtracellular matrix regulation of YAP and TAZ signaling mechanobiology and therapeutic opportunities
- Open Access
- 5 February 2026
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 6 (1) , 16-38
Cardiac disease in systemic sclerosis: Integrating pathobiology with clinical management
Systemic sclerosis (SSc) is a complex autoimmune disorder in which cardiovascular involvement remains a major determinant of morbidity and mortality. Cardiac injury in SSc results from the interplay of microvascular dysfunction, immune‐mediated inflammation, and progressive interstitial and replacement fibrosis, leading to myocardial disease, arrhythmias, pericardial abnormalities, and coronary microvascular ischemia. Many of these manifestations evolve silently, becoming clinically apparent only after substantial structural or electrical remodeling has occurred, highlighting the critical need for systematic surveillance. Current consensus algorithms recommend a core annual cardiovascular assessment—including symptom‐directed clinical evaluation, electrocardiography, transthoracic echocardiography with tissue Doppler and strain imaging, and measurement of natriuretic peptides and high‐sensitivity troponin—with escalation to cardiac magnetic resonance imaging, ambulatory rhythm monitoring, or stress testing when abnormalities are detected. Management integrates standard heart failure and arrhythmia therapies with judicious use of immunomodulation in patients with active inflammatory cardiomyopathy. However, evidence for targeted immunosuppressive treatment of primary cardiac involvement in SSc remains limited, and the optimal frequency, modality, and biomarker combinations for screening continue to be refined. This review synthesizes emerging mechanisms, diagnostic strategies, and therapeutic considerations, and outlines research priorities aimed at improving early detection and outcomes in cardiovascular manifestations of SSc.
- 5 February 2026
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 6 (1) , 16-38
Open AccessCardiac disease in systemic sclerosis: Integrating pathobiology with clinical management
Systemic sclerosis (SSc) is a complex autoimmune disorder in which cardiovascular involvement remains a major determinant of morbidity and mortality. Cardiac injury in SSc results from the interplay of microvascular dysfunction, immune‐mediated inflammation, and progressive interstitial and replacement fibrosis, leading to myocardial disease, arrhythmias, pericardial abnormalities, and coronary microvascular ischemia. Many of these manifestations evolve silently, becoming clinically apparent only after substantial structural or electrical remodeling has occurred, highlighting the critical need for systematic surveillance. Current consensus algorithms recommend a core annual cardiovascular assessment—including symptom‐directed clinical evaluation, electrocardiography, transthoracic echocardiography with tissue Doppler and strain imaging, and measurement of natriuretic peptides and high‐sensitivity troponin—with escalation to cardiac magnetic resonance imaging, ambulatory rhythm monitoring, or stress testing when abnormalities are detected. Management integrates standard heart failure and arrhythmia therapies with judicious use of immunomodulation in patients with active inflammatory cardiomyopathy. However, evidence for targeted immunosuppressive treatment of primary cardiac involvement in SSc remains limited, and the optimal frequency, modality, and biomarker combinations for screening continue to be refined. This review synthesizes emerging mechanisms, diagnostic strategies, and therapeutic considerations, and outlines research priorities aimed at improving early detection and outcomes in cardiovascular manifestations of SSc.
- Open Access
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 72
A narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances
Introduction: Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. Methodology: This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Discussion: Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Future directions: Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Conclusion: Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 72
Open AccessA narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances
Introduction: Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. Methodology: This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Discussion: Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Future directions: Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Conclusion: Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.
- Open Access
- 26 November 2025
- Published by Elsevier in Clinical Immunology Communications
- Vol. 8, 138-158
The immunological nexus between inflammatory bowel disease and colorectal cancer: A molecular perspective
- 26 November 2025
- Published by Elsevier in Clinical Immunology Communications
- Vol. 8, 138-158
Open AccessThe immunological nexus between inflammatory bowel disease and colorectal cancer: A molecular perspective
- 26 June 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (7) , 696-722
Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity
T‐helper 17 (Th17) cells, a subset of CD4+ T cells, are key players in mucosal immunity and inflammation, distinguished by their production of IL‐17 and related cytokines. In the context of cancer, Th17 cells exhibit extraordinary plasticity—adapting their phenotype and function in response to tumor microenvironmental cues. This review explores how Th17 cells mediate paradoxical roles in tumor biology, promoting either tumor progression or antitumor immunity depending on molecular context. Protumorigenic functions include fostering angiogenesis, chronic inflammation and immune evasion through IL‐17‐driven recruitment of neutrophils and myeloid‐derived suppressor cells. Conversely, Th17 cells can transition into IFNγ‐producing Th1‐like cells, enhancing cytotoxic T‐cell responses and tumor rejection. Key modulators of this plasticity include cytokines (IL‐23, IL‐12, TGF‐β), hypoxia, metabolic shifts and epigenetic reprogramming. We further examine how Th17 plasticity contributes to metastasis, therapy resistance and immune modulation via interactions with tumor‐associated macrophages and regulatory T cells. Finally, the review highlights emerging therapeutic strategies that target Th17 pathways through cytokine blockade, metabolic intervention, RORγ modulation and adoptive cell therapy. Understanding Th17 plasticity provides critical insights into tumor immunology and offers novel avenues for cancer immunotherapy.
- 26 June 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (7) , 696-722
Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity
T‐helper 17 (Th17) cells, a subset of CD4+ T cells, are key players in mucosal immunity and inflammation, distinguished by their production of IL‐17 and related cytokines. In the context of cancer, Th17 cells exhibit extraordinary plasticity—adapting their phenotype and function in response to tumor microenvironmental cues. This review explores how Th17 cells mediate paradoxical roles in tumor biology, promoting either tumor progression or antitumor immunity depending on molecular context. Protumorigenic functions include fostering angiogenesis, chronic inflammation and immune evasion through IL‐17‐driven recruitment of neutrophils and myeloid‐derived suppressor cells. Conversely, Th17 cells can transition into IFNγ‐producing Th1‐like cells, enhancing cytotoxic T‐cell responses and tumor rejection. Key modulators of this plasticity include cytokines (IL‐23, IL‐12, TGF‐β), hypoxia, metabolic shifts and epigenetic reprogramming. We further examine how Th17 plasticity contributes to metastasis, therapy resistance and immune modulation via interactions with tumor‐associated macrophages and regulatory T cells. Finally, the review highlights emerging therapeutic strategies that target Th17 pathways through cytokine blockade, metabolic intervention, RORγ modulation and adoptive cell therapy. Understanding Th17 plasticity provides critical insights into tumor immunology and offers novel avenues for cancer immunotherapy.
- Open Access
- 25 April 2024
- Published by Elsevier in Cancer Pathogenesis and Therapy
- Vol. 3 (2) , 101-108
Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management
- 25 April 2024
- Published by Elsevier in Cancer Pathogenesis and Therapy
- Vol. 3 (2) , 101-108
Open AccessCardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management
- Open Access
- 1 December 2022
- Published by Institute of Advanced Engineering and Science in International Journal of Public Health Science (IJPHS)
- Vol. 11 (4) , 1458-1465
Colchicine as adjuvant therapy in COVID-19 patients: a meta-analysis
SARS-CoV-2 infection results in hyperinflammatory responses by activating proinflammatory cytokines and chemokines. Colchicine is an anti-inflammatory drug that reduces superoxide production, tumor necrosis factor alpha (TNF-α) activation, and neutrophil chemotaxis. This study aimed to understand the effect of adjuvant colchicine on mortality in COVID-19 patients. Systematic literature searching was conducted on PubMed, ScienceDirect, Cochrane Library, and medRxiv with keywords colchicine, coronavirus disease, COVID-19, mortality, and SARS-CoV-2. Five randomized controlled studies with 15,779 patients were included. There was no significant difference between the colchicine group and the standard group (OR 1.00 [95% CI 0.91-1.09], p=0.94); invasive mechanical ventilation necessity also did not show a significant difference (OR 0.99 [95% CI 0.83-1.17 p=0.88). There was no significant difference in the incidence of cardiovascular disease (OR 1.11 [95% CI 0.50-2.46], p=0.79), also the incidence of pneumonia was lower in colchicine group (OR 0.68 [95% CI 0.49-0.93], p=0.02), while the incidence of gastrointestinal complaints was higher in colchicine group (OR 2.09 [95% CI 1.84-2.37], p<0.00001). Colchicine as COVID-19 adjuvant therapy did not significantly reduce mortality, the need for invasive mechanical ventilation, and the incidence of cardiovascular disease. Furthermore, the colchicine group had lower pneumonia incidence and higher gastrointestinal complaint incidence.
- 1 December 2022
- Published by Institute of Advanced Engineering and Science in International Journal of Public Health Science (IJPHS)
- Vol. 11 (4) , 1458-1465
Open AccessColchicine as adjuvant therapy in COVID-19 patients: a meta-analysis
SARS-CoV-2 infection results in hyperinflammatory responses by activating proinflammatory cytokines and chemokines. Colchicine is an anti-inflammatory drug that reduces superoxide production, tumor necrosis factor alpha (TNF-α) activation, and neutrophil chemotaxis. This study aimed to understand the effect of adjuvant colchicine on mortality in COVID-19 patients. Systematic literature searching was conducted on PubMed, ScienceDirect, Cochrane Library, and medRxiv with keywords colchicine, coronavirus disease, COVID-19, mortality, and SARS-CoV-2. Five randomized controlled studies with 15,779 patients were included. There was no significant difference between the colchicine group and the standard group (OR 1.00 [95% CI 0.91-1.09], p=0.94); invasive mechanical ventilation necessity also did not show a significant difference (OR 0.99 [95% CI 0.83-1.17 p=0.88). There was no significant difference in the incidence of cardiovascular disease (OR 1.11 [95% CI 0.50-2.46], p=0.79), also the incidence of pneumonia was lower in colchicine group (OR 0.68 [95% CI 0.49-0.93], p=0.02), while the incidence of gastrointestinal complaints was higher in colchicine group (OR 2.09 [95% CI 1.84-2.37], p<0.00001). Colchicine as COVID-19 adjuvant therapy did not significantly reduce mortality, the need for invasive mechanical ventilation, and the incidence of cardiovascular disease. Furthermore, the colchicine group had lower pneumonia incidence and higher gastrointestinal complaint incidence.
- Open Access
- 31 August 2021
- Published by Universitas Mulawarman in Jurnal Sains dan Kesehatan
- Vol. 3 (4) , 390-395
Hubungan Kadar Hemoglobin Terglikosilasi (HbA1c) dengan Estimasi Laju Filtrasi Glomerulus (eLFG) Pasien DM Tipe II di Fasilitas Kesehatan Tingkat Pertama
Diabetes melitus (DM) tipe II merupakan penyakit metabolik yang prevalensinya semakin meningkat dan dapat menimbulkan komplikasi jangka panjang, salah satunya berupa penyakit ginjal diabetik ditandai penurunan estimasi laju filtrasi glomerulus (eLFG). Fasilitas Kesehatan Tingkat Pertama (FKTP) diharapkan dapat mengelola penyakit kronis seperti DM tipe II, sehingga meminimalkan komplikasi mikrovaskular maupun makrovaskular sejak dini. Penelitian ini bertujuan untuk mengetahui hubungan kadar HbA1c dengan eLFG pasien DM tipe II di FKTP. Penelitian ini merupakan studi analitik korelatif cross-sectional, mengumpulkan data rekam medis 64 pasien DM tipe II yang terdaftar Prolanis (program pengelolaan penyakit kronis) salah satu FKTP di Samarinda. Analisis menggunakan uji pearson. Hasil penelitian didapatkan 64 subjek yang diperiksa, rerata usia 58,45 tahun, terdiri atas 26 laki laki (40,6%) dan 38 perempuan (59,4%). Rerata kadar HbA1c 7,6%, sedangkan rerata eLFG 60,04 mL/min/1.73m2. kesimpulan penelitian ini terdapat hubungan signifikan antara kadar HbA1c dengan eLFG berupa korelasi negatif (r=-0,404; p=0,001). Sehingga, diperlukan strategi pengelolaan DM tipe II yang optimal dari FKTP untuk meminimalkan komplikasi jangka Panjang.
- 31 August 2021
- Published by Universitas Mulawarman in Jurnal Sains dan Kesehatan
- Vol. 3 (4) , 390-395
Open AccessHubungan Kadar Hemoglobin Terglikosilasi (HbA1c) dengan Estimasi Laju Filtrasi Glomerulus (eLFG) Pasien DM Tipe II di Fasilitas Kesehatan Tingkat Pertama
Diabetes melitus (DM) tipe II merupakan penyakit metabolik yang prevalensinya semakin meningkat dan dapat menimbulkan komplikasi jangka panjang, salah satunya berupa penyakit ginjal diabetik ditandai penurunan estimasi laju filtrasi glomerulus (eLFG). Fasilitas Kesehatan Tingkat Pertama (FKTP) diharapkan dapat mengelola penyakit kronis seperti DM tipe II, sehingga meminimalkan komplikasi mikrovaskular maupun makrovaskular sejak dini. Penelitian ini bertujuan untuk mengetahui hubungan kadar HbA1c dengan eLFG pasien DM tipe II di FKTP. Penelitian ini merupakan studi analitik korelatif cross-sectional, mengumpulkan data rekam medis 64 pasien DM tipe II yang terdaftar Prolanis (program pengelolaan penyakit kronis) salah satu FKTP di Samarinda. Analisis menggunakan uji pearson. Hasil penelitian didapatkan 64 subjek yang diperiksa, rerata usia 58,45 tahun, terdiri atas 26 laki laki (40,6%) dan 38 perempuan (59,4%). Rerata kadar HbA1c 7,6%, sedangkan rerata eLFG 60,04 mL/min/1.73m2. kesimpulan penelitian ini terdapat hubungan signifikan antara kadar HbA1c dengan eLFG berupa korelasi negatif (r=-0,404; p=0,001). Sehingga, diperlukan strategi pengelolaan DM tipe II yang optimal dari FKTP untuk meminimalkan komplikasi jangka Panjang.